Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MYKACET vs ANEXSIA 7.5/325
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
MYKACET (acetaminophen) is a centrally acting analgesic and antipyretic. Its exact mechanism is not fully understood, but it is thought to involve inhibition of cyclooxygenase (COX) isoenzymes in the central nervous system, particularly COX-2, and modulation of descending serotonergic pathways.
Hydrocodone is a mu-opioid receptor agonist, producing analgesia and euphoria. Acetaminophen inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis and providing analgesic and antipyretic effects.
Mild to moderate pain,Fever
Management of moderate to moderately severe pain where treatment with an opioid is appropriate and for which alternative treatments are inadequate
4 g intravenous every 8 hours over 3 hours, based on piperacillin 4 g and tazobactam 0.5 g.
1 tablet (hydrocodone 7.5 mg / acetaminophen 325 mg) orally every 4 to 6 hours as needed for pain; maximum 6 tablets per day (hydrocodone 45 mg / acetaminophen 1950 mg).
Terminal elimination half-life is approximately 2-4 hours in patients with normal renal function; extended to 12-24 hours in moderate to severe renal impairment (Cr Cl <30 m L/min), requiring dose adjustment.
Hydrocodone: 3.8-4.5 hours (immediate-release). Acetaminophen: 2-3 hours. Clinical note: Half-life prolonged in hepatic impairment; requires dose adjustment.
Acetaminophen is extensively metabolized in the liver via conjugation with glucuronic acid (glucuronidation) and sulfuric acid (sulfation). A minor metabolite (N-acetyl-p-benzoquinone imine, NAPQI) is formed via cytochrome P450 isoenzymes (CYP2E1, CYP1A2, CYP3A4) and is primarily detoxified by conjugation with glutathione.
Hydrocodone: CYP3A4 and CYP2D6; Acetaminophen: primarily via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation, with minor oxidation by CYP2E1.
Primarily renal excretion of unchanged drug via glomerular filtration and active tubular secretion; >90% of administered dose appears in urine within 24 hours; minimal biliary/fecal elimination (<5%).
Renal: ~90-100% as hydrocodone metabolites (conjugated) and unchanged hydrocodone; ~60% as acetaminophen metabolites (glucuronide, sulfate, cysteine); <5% unchanged acetaminophen. Biliary/fecal: <5%.
Approximately 20-30% bound to serum proteins, primarily albumin.
Hydrocodone: ~20-30% (albumin). Acetaminophen: ~10-25% (albumin).
Volume of distribution is 0.3-0.5 L/kg, indicating distribution primarily into extracellular fluid; does not extensively penetrate tissues or cross the blood-brain barrier.
Hydrocodone: 3-4 L/kg (extensive tissue distribution). Acetaminophen: ~1 L/kg (uniformly distributed).
Oral bioavailability is approximately 50-70% due to first-pass metabolism; intravenous administration yields 100% bioavailability.
Oral: Hydrocodone ~70% (high first-pass metabolism); Acetaminophen ~85-90% (minimal first-pass).
For Cr Cl 20-40 m L/min: 3 g (piperacillin 3 g / tazobactam 0.375 g) q8h; Cr Cl <20 m L/min: 2 g (piperacillin 2 g / tazobactam 0.25 g) q12h.
For GFR 30-59 m L/min: administer every 6 hours; maximum 4 tablets per day. For GFR 15-29 m L/min: administer every 8 hours; maximum 3 tablets per day. For GFR <15 m L/min: not recommended due to accumulation of metabolites.
No dose adjustment required for hepatic impairment; use standard dosing.
Child-Pugh Class A: no adjustment necessary. Child-Pugh Class B: reduce dose by 25-50% and extend dosing interval to every 6-8 hours; maximum 4 tablets per day. Child-Pugh Class C: contraindicated due to risk of hepatotoxicity.
For infants >2 months and children <40 kg: 100 mg/kg piperacillin component every 8 hours; for children ≥40 kg: adult dose (4 g q8h).
Not recommended for pediatric patients; safety and efficacy not established for children under 18 years. For adolescents ≥18 years: adult dosing.
Adjust dose based on renal function; no specific age-related adjustments beyond renal dosing.
Initiate at 1 tablet (hydrocodone 5 mg / acetaminophen 325 mg) every 6 hours as needed; titrate cautiously due to increased sensitivity, decreased renal function, and risk of respiratory depression. Maximum 4 tablets per day.
Acetaminophen has been associated with cases of acute liver failure, sometimes resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed the maximum daily dose (4 grams/day).
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity due to acetaminophen.
Hepatotoxicity: Risk of acute liver failure with doses exceeding 4g/day, in patients with pre-existing liver disease, or with chronic alcohol use.,Serious skin reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis can occur at any dose.,Hypersensitivity reactions: Anaphylaxis and angioedema.
Risk of opioid addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use of alcohol, benzodiazepines, or other CNS depressants; hepatotoxicity; severe hypotension; adrenal insufficiency; seizures; GI obstruction; impaired mental/physical abilities; use in elderly, cachectic, or debilitated patients; renal impairment; hepatic impairment; pregnancy; labor and delivery; nursing mothers; pediatric use; driving and operating machinery.
Hypersensitivity to acetaminophen or any component of the formulation,Severe hepatic impairment or active liver disease
Significant respiratory depression; acute or severe bronchial asthma; known or suspected GI obstruction; hypersensitivity to hydrocodone or acetaminophen; concomitant use of MAOIs or within 14 days of such therapy.
Grapefruit juice decreases mycophenolic acid exposure; avoid grapefruit products. High-fat meals reduce absorption; take on empty stomach. Cholestyramine reduces absorption; separate administration by at least 2 hours. Antacids containing magnesium or aluminum should be separated by 2 hours.
Avoid alcohol consumption due to increased risk of acetaminophen hepatotoxicity and CNS depression. No specific food restrictions, but grapefruit juice may theoretically affect hydrocodone metabolism via CYP3A4 inhibition; however, clinical significance is uncertain.
MYKACET (acalabrutinib) is a BTK inhibitor. In animal studies, embryo-fetal toxicity was observed at maternal exposures below clinical doses. In pregnant women, no adequate data; however, based on mechanism of action, there is potential for fetal harm, particularly during organogenesis (first trimester). Avoid use in pregnancy unless benefit outweighs risk.
FDA Category C (hydrocodone) and Category D (acetaminophen) in third trimester. First trimester: Acetaminophen associated with rare gastroschisis; hydrocodone risk of neural tube defects. Second trimester: No major malformations except with prolonged opioid use. Third trimester: Acetaminophen safe; hydrocodone risk of neonatal opioid withdrawal syndrome (NOWS). Avoid near term.
No data on presence in human milk, effects on milk production, or nursing infant. Animal studies show drug and metabolites present in milk. Because of potential for serious adverse reactions in breastfed infants, advise women to discontinue breastfeeding during treatment and for 2 weeks after last dose. M/P ratio: unknown.
Hydrocodone/acetaminophen excreted in breast milk. M/P ratio unknown. Hydrocodone relative infant dose <3% of weight-adjusted maternal dose. Acetaminophen relative infant dose <2%. Use with caution; monitor infant for sedation, apnea, poor feeding. Highest risk in CYP2D6 ultrarapid metabolizers.
No specific dosing recommendations in pregnancy due to lack of data. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered clearance) may necessitate dose adjustment, but no established guidelines. Use lowest effective dose if unavoidable; monitor for toxicity and efficacy.
Increased clearance of hydrocodone in pregnancy may require dose adjustment; monitor for inadequate analgesia. Acetaminophen pharmacokinetics unchanged. Avoid high doses (hepatotoxicity risk). Consider baseline hepatic function. No specific dose adjustment recommended; titrate to effect.
Mykacet (mycophenolic acid) requires monitoring of complete blood counts due to risk of bone marrow suppression; dose adjustment needed in renal impairment. Avoid concomitant use with azathioprine; administer on empty stomach for consistent absorption. Levels may be affected by cholestyramine or antacids.
ANEXSIA 7.5/325 (hydrocodone/acetaminophen) carries a boxed warning for acetaminophen hepatotoxicity; maximum acetaminophen dose from all sources should not exceed 4 g/day. Hydrocodone is metabolized by CYP2D6 to hydromorphone; ultrarapid metabolizers may experience toxicity. Avoid concurrent use with other CNS depressants including alcohol. Prescribe with caution in patients with renal impairment (hydrocodone accumulation) or hepatic impairment (acetaminophen toxicity). Monitor for signs of respiratory depression, especially at therapy initiation and dose titration. Use the lowest effective dose for the shortest duration.
Take capsules on an empty stomach, 1 hour before or 2 hours after meals.,Do not crush or chew capsules; swallow whole.,Avoid grapefruit juice and other grapefruit products during treatment.,Use effective contraception during and for 6 weeks after stopping therapy due to teratogenic risk.,Report any signs of infection (fever, sore throat) or unusual bruising/bleeding immediately.,Avoid live vaccines; discuss vaccination schedule with your doctor.,Take exactly as prescribed; do not stop without consulting your healthcare provider.
Do not exceed 6 tablets per day due to acetaminophen content.,Avoid alcohol while taking this medication.,Do not drive or operate heavy machinery until you know how this medication affects you.,Take exactly as prescribed; do not share with others.,Seek emergency help if you experience difficulty breathing, severe drowsiness, or signs of allergic reaction.,Store securely out of reach of children and dispose of unused medication properly.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MYKACET vs ANEXSIA 7.5/325, answered by our medical review team.
MYKACET is a Opioid Analgesic Combination that works by MYKACET (acetaminophen) is a centrally acting analgesic and antipyretic. Its exact mechanism is not fully understood, but it is thought to involve inhibition of cyclooxygenase (COX) isoenzymes in the central nervous system, particularly COX-2, and modulation of descending serotonergic pathways.. ANEXSIA 7.5/325 is a Opioid Analgesic Combination that works by Hydrocodone is a mu-opioid receptor agonist, producing analgesia and euphoria. Acetaminophen inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis and providing analgesic and antipyretic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MYKACET and ANEXSIA 7.5/325 depend on the specific clinical indication. These are both Opioid Analgesic Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MYKACET is: 4 g intravenous every 8 hours over 3 hours, based on piperacillin 4 g and tazobactam 0.5 g.. The standard adult dose of ANEXSIA 7.5/325 is: 1 tablet (hydrocodone 7.5 mg / acetaminophen 325 mg) orally every 4 to 6 hours as needed for pain; maximum 6 tablets per day (hydrocodone 45 mg / acetaminophen 1950 mg).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MYKACET and ANEXSIA 7.5/325 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MYKACET is classified as Category C. MYKACET (acalabrutinib) is a BTK inhibitor. In animal studies, embryo-fetal toxicity was observed at maternal exposures below clinical doses. In pregnant women, no adequate data; h. ANEXSIA 7.5/325 is classified as Category C. FDA Category C (hydrocodone) and Category D (acetaminophen) in third trimester. First trimester: Acetaminophen associated with rare gastroschisis; hydrocodone risk of neural tube d. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.